格隆汇12月16日丨玮俊生物科技(00660.HK)公布,集团预期截至2024年6月30日止年度将录得综合净亏损介乎5700万港元至6200万港元,而截至2023年6月30日止年度净亏损约1000万港元。预期公司综合净亏损增加主要是由于(其中包括)毛利减少约1620万港元及物业、厂房及设备减值亏损约5180万港元。【免责声明】本文仅代表作者本人观点,与和讯网无关。和讯网站对文中陈述、观点判断...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.